Reply to: 'Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma'
- PMID: 35526788
- DOI: 10.1016/j.jhep.2022.04.029
Reply to: 'Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma'
Conflict of interest statement
Conflict of interest The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment on
-
Baveno VII - Renewing consensus in portal hypertension.J Hepatol. 2022 Apr;76(4):959-974. doi: 10.1016/j.jhep.2021.12.022. Epub 2021 Dec 30. J Hepatol. 2022. PMID: 35120736 Free PMC article. Review.
-
Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma.J Hepatol. 2022 Aug;77(2):566-567. doi: 10.1016/j.jhep.2022.02.004. Epub 2022 Feb 17. J Hepatol. 2022. PMID: 35182660 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical

